Docetaxel and alpha-lipoic acid co-loaded nanoparticles for cancer therapy. (17th April 2019)

• Record Type: Journal Article
• Authors: Kothari, Ishit R; Mazumdar, Samrat; Sharma, Saurabh; Italiya, Kishan; Mittal, Anupama; Chitkara, Deepak
• Is Part Of: Therapeutic delivery. Volume 10:Number 4(2019)
• Page Start: 227
• Page End: 240
• Publication Date: 2019-04-17
• Subjects: breast cancer -- co-delivery -- docetaxel -- solid lipid nanoparticles -- uptake; Drug delivery systems -- Periodicals; Therapeutics -- Periodicals; 615.6
• DOI: 10.4155/tde-2018-0074
• Languages: English
• ISSNs: 2041-5990

Abstract

Aim: The current study aims to co-deliver docetaxel (DTX) and alpha-lipoic acid (ALA) using solid lipid nanoparticles (SLNs) as a carrier for the treatment of breast cancer.Methods: Computational analysis was used to screen different solid lipids as carriers, following which SLNs were prepared and characterized. Furthermore, antioxidant activity assays and cell culture studies were performed.Results: In vitro assessment in 4T1 (murine mammary carcinoma) and MCF-7 (human breast adenocarcinoma) cells revealed enhanced efficacy of the co-loaded SLNs as compared with free drugs and single drug-loaded SLNs. Increased apoptosis following treatment with DTX-ALA co-loaded SLN was also observed.Conclusion: The developed SLNs showed significantly higher uptake efficiency along with improved cytotoxic and apoptotic potential indicating the usefulness of this combination.